Boryung, HK inno.N to co-market Kanarb, K-CAB

South Korea’s pharmaceutical companies Boryung Corp. and HK inno.N announced on Wednesday that they will start co-marketing for their respective blockbuster drugs Kanarb and K-CAB in January next year.  

This deal is the first collaboration between domestic pharmaceutical companies that have developed blockbuster new drugs with annual sales exceeding 100 billion won ($76.98 million).

Under the agreement, Boryung will take over marketing for all K-CAB products, including tablets and orally disintegrating tablets. HK inno.N will manage the four types of Kanarb: Kanarb, Dukaro, Dukarb, and Dukarb Plus.

Medical Market research firm UBIST reports that K-CAB, a treatment for gastroesophageal reflux disease, recorded sales of 132.1 billion won ($101 million) last year. Meanwhile, Kanarb, a hypertension treatment, generated 150.3 billion won ($115 million) in 2022 across seven product variations.